Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

Group leaders

Francisco Javier López Jiménez

José Valentín García Gutiérrez

jljimenez(ELIMINAR)@salud.madrid.org

Tlf.: + 34 91 3368967

Principal Investigator

  • Alejandro Luna de Abia

Collaborating Staff

  • Pilar Herrera Puente
  • Gemma Moreno Jiménez
  • Miguel Piris Villaespesa
  • Juan Marquet Palomares
  • María Jesús Blanchard Rodríguez
  • Anabelle Chinea Rodríguez
  • María Concepción Tenorio Núñez
  • Maria del Mar Meijon Ortigueira
  • Ana Lario Arribas
  • Fernando Martín Moro
  • Kyra Velázquez Kennedy
  • Claudia Nuñez-Torron Stock
  • Gerónimo Fernández Gómez-Chacón
Imagen equipo

Group leaders

Francisco Javier López Jiménez

José Valentín García Gutiérrez

jljimenez(ELIMINAR)@salud.madrid.org

Tlf.: + 34 91 3368967

Principal Investigator

  • Alejandro Luna de Abia

Collaborating Staff

  • Pilar Herrera Puente
  • Gemma Moreno Jiménez
  • Miguel Piris Villaespesa
  • Juan Marquet Palomares
  • María Jesús Blanchard Rodríguez
  • Anabelle Chinea Rodríguez
  • María Concepción Tenorio Núñez
  • Maria del Mar Meijon Ortigueira
  • Ana Lario Arribas
  • Fernando Martín Moro
  • Kyra Velázquez Kennedy
  • Claudia Nuñez-Torron Stock
  • Gerónimo Fernández Gómez-Chacón

STRATEGIC OBJECTIVES

  • To identify new pathways involved in the immune response to hematological malignancies and infections amenable to therapeutic intervention.
  • To study therapeutic strategies in patients undergoing hematopoietic stem cell transplantation to optimize graft-versus-disease effectiveness.
  • To develop cell therapy for clinical and research purposes with applications in medical and surgical specialties.
  • To implement immunophenotypic diagnosis of hematological malignancies for the application of targeted therapies (individualized treatment) and improved monitoring of residual disease.
  • To optimize transfusion therapy strategies.
  • To integrate multidisciplinary teams in the management of frail patients with hematological malignancies.
  • To promote multidisciplinary teams for the prevention and management of long-term complications resulting from current treatments.
  • To enhance participation and foster leadership in national and international cooperative groups and real-world evidence registries.
  • To secure funding from public and private entities for the group's sustainability and growth.

RESEARCH LINES

  • Study of the immune system's response to pathogens in hematologic malignancies.
  • Effect of the immune response against hematologic malignancies and its modulation by new drugs.
  • Cell therapy in patients undergoing hematopoietic stem cell transplantation and non-neoplastic diseases.
  • Study and prevention of cardiac dysfunction secondary to certain drugs.
  • Search for predictive factors of response in myeloproliferative neoplasms.
  • Clinical and biological characterization (lymph node and bone marrow) of chronic B-cell lymphoproliferative syndromes.
  • Implementation of genetic diagnostic analysis in the diagnosis of red blood cell diseases to establish phenotype-genotype relationships.
  • Development of diagnostic algorithms with serological and genetic tests to facilitate the resolution of complex immunohematologic problems in transfusion medicine.
  • Study of the long-term side effects of conventional chemotherapy and new drugs.

Location

Ramón y Cajal University Hospital

Hematology Department
8th Floor, Central Building

Keywords

Translational hematology, oncohematology, immune reconstitution, cell therapy, hematopoietic stem cell transplantation, myeloproliferative neoplasms, lymphoproliferative syndromes, coagulopathies, transfusion therapy